Article
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Jul 2023
Peng Ping, Gong Juejun, Zhang Yujie, Zhou Shuchang, Li Yichen, Han Guang, Meng Rui, Chen Yongshun, Yang Ming, Shen Qian, Chu Qian, Xia Shu, Zhang Peng, Zhang Lu, Chen Yuan, Zhang Li
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.